0000000000756461

AUTHOR

Danilo Fliser

showing 4 related works from this author

Inflammation is an amplifier of lung congestion by high lv filling pressure in hemodialysis patients: a longitudinal study

2019

Introduction Since infammation alters vascular permeability, including vascular permeability in the lung, we hypothesized that it can be an amplifer of lung congestion in a category of patients at high risk for pulmonary oedema like end stage kidney disease (ESKD) patients. Objective and methods We investigated the efect modifcation by systemic infammation (serum CRP) on the relationship between a surrogate of the flling pressure of the LV [left atrial volume indexed to the body surface area (LAVI)] and lung water in a series of 220 ESKD patients. Lung water was quantifed by the number of ultrasound B lines (US-B) on lung US. Six-hundred and three recordings were performed during a 2-year f…

Nephrologymedicine.medical_specialtymedicine.medical_treatment030232 urology & nephrologyInflammationVascular permeabilityInfammation030204 cardiovascular system & hematologySystemic inflammation03 medical and health sciences0302 clinical medicineRenal DialysisPulmonary edemaInternal medicinemedicineHumansLongitudinal StudiesLung congestionESRDLungInflammationBody surface areaLungbusiness.industryCardiovascular riskPulmonary edemamedicine.diseasemedicine.anatomical_structureNephrologyHemodialysisCardiologyHemodialysismedicine.symptombusinessJournal of Nephrology
researchProduct

A randomized multicenter trial on a lung ultrasound-guided treatment strategy in patients on chronic hemodialysis with high cardiovascular risk

2021

Lung congestion is a risk factor for all-cause and cardiovascular mortality in patients on chronic hemodialysis, and its estimation by ultrasound may be useful to guide ultrafiltration and drug therapy in this population. In an international, multi-center randomized controlled trial (NCT02310061) we investigated whether a lung ultrasound-guided treatment strategy improved a composite end point (all-cause death, non-fatal myocardial infarction, decompensated heart failure) vs usual care in patients receiving chronic hemodialysis with high cardiovascular risk. Patient-Reported Outcomes (Depression and the Standard Form 36 Quality of Life Questionnaire, SF36) were assessed as secondary outcome…

cardiovascular riskmedicine.medical_specialtymedicine.medical_treatmentPopulationlung congestionlaw.inventionKidney FailureRandomized controlled trialRenal DialysisRisk FactorslawMulticenter trialInternal medicineHumansMedicineChronicRisk factorESRDeducationLungUltrasonography InterventionalDialysisUltrasonographylung ultrasoundeducation.field_of_studyInterventionalbusiness.industryHazard ratiochronic kidney failuremedicine.diseaseESRD; cardiovascular risk; chronic kidney failure; heart failure hemodialysis; lung congestion; lung ultrasoundHeart Disease Risk FactorsCardiovascular DiseasesNephrologyHeart failureQuality of LifeKidney Failure ChronicHemodialysisheart failure hemodialysisbusinessKidney international
researchProduct

Cholesteryl ester transfer protein activity and cardiovascular events in patients with chronic kidney disease stage V.

2008

Background Patients with chronic kidney disease (CKD) have an increased risk for cardiovascular events (CVE). Uraemic dyslipidaemia, which is characterized by low HDL-cholesterol (HDL-C) and elevated triglycerides' levels, may contribute to this elevated cardiovascular risk. Cholesteryl ester transfer protein (CETP) lowers HDL-C by transferring cholesterol esters to LDL and VLDL particles. We tested the hypothesis that CETP activity is associated with CVE in patients with CKD stage V. Methods We measured CETP activity and cholesterol levels in 69 haemodialysis patients. CVE and death were prospectively assessed over a follow-up period of 48 months. Results CETP activity was negatively corre…

MaleVery low-density lipoproteinmedicine.medical_specialtymedicine.medical_treatmentMyocardial InfarctionKaplan-Meier EstimateSeverity of Illness IndexCohort Studieschemistry.chemical_compoundPredictive Value of TestsRisk FactorsInternal medicineCholesterylester transfer proteinmedicineHumansMyocardial infarctionProspective StudiesAngioplasty Balloon CoronaryCoronary Artery BypassProspective cohort studyStrokeAgedAged 80 and overTransplantationbiologybusiness.industryCholesterolCholesterol HDLMiddle Agedmedicine.diseaseCholesterol Ester Transfer Proteinscarbohydrates (lipids)StrokeEndocrinologychemistryNephrologyChronic Diseasebiology.proteinlipids (amino acids peptides and proteins)FemaleKidney DiseasesStentsHemodialysisbusinessBiomarkersKidney diseaseFollow-Up StudiesNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
researchProduct

CKD NUTRITION, INFLAMMATION AND OXIDATIVE STRESS

2014

Introduction and Aims: Serum p-cresyl sulfate associates with cardiovascular disease in patients at different stages of chronic kidney disease. p-Cresyl sulfate concentrations are determined by intestinal uptake of p-cresol, human metabolism to p-cresyl sulfate and renal clearance. Whether intestinal uptake of p-cresol itself is associated with cardiovascular disease in patients with renal disease has not been studied to date. Methods: We performed a prospective study in patients with chronic kidney disease stage 1-5 (clinicaltrials.gov NCT00441623). Intestinal uptake of p-cresol, under steady state conditions, was estimated from 24h urinary excretion of p-cresyl sulfate. Primary endpoint w…

Transplantationmedicine.medical_specialtyFramingham Risk ScoreCardiovascular Historybusiness.industryHazard ratioRenal functionmedicine.diseaseGastroenterologyEndocrinologyNephrologyDiabetes mellitusInternal medicinemedicineMyocardial infarctionProspective cohort studybusinessKidney diseaseNephrology Dialysis Transplantation
researchProduct